TB-500 (Thymosin Beta-4): Research Overview and Mechanisms
TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring 43-amino acid peptide involved in actin sequestration, cell migration, and tissue repair processes.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any health decisions.
What Is TB-500?
TB-500 is a synthetic analogue of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide encoded by the TMSB4X gene. Thymosin Beta-4 was first isolated from bovine thymus tissue in the 1960s and has since been identified in virtually all nucleated mammalian cells.
The peptide's primary biological role involves binding G-actin (globular actin) monomers, thereby regulating the availability of actin for polymerisation into F-actin (filamentous actin). This actin-sequestering function places Thymosin Beta-4 at the centre of cell motility, wound healing, and tissue remodelling research.
Molecular Characteristics
| Property | Value | |----------|-------| | Molecular Formula | C212H350N56O78S | | Molecular Weight | ~4963.5 Da | | CAS Number | 77591-33-4 | | Sequence | SDKPDMAEIEKFDKSKLKKTTETQ... (43 aa) | | Format | Lyophilized powder |
Key Research Areas
Actin Dynamics and Cell Migration The primary mechanism of Thymosin Beta-4 is its sequestration of G-actin monomers through a high-affinity binding interaction. Research has shown this regulates the actin treadmilling cycle, directly influencing lamellipodia formation and directed cell migration — processes fundamental to wound closure and tissue regeneration.
Cardiac Repair Some of the most compelling preclinical data involves cardiac models. Studies in rodents following myocardial infarction have reported that Thymosin Beta-4 treatment was associated with cardiomyocyte survival, reduced infarct size, and improved functional recovery. Researchers have proposed epicardial progenitor cell activation as a contributing mechanism.
Angiogenesis TB-500 has been studied for its pro-angiogenic properties. In vitro and in vivo models have shown upregulation of VEGF and other angiogenic markers, with histological evidence of increased capillary density in treated tissues.
Anti-inflammatory Effects Several studies have examined Thymosin Beta-4's interaction with NF-κB signalling pathways, reporting reduced pro-inflammatory cytokine expression (TNF-α, IL-1β, IL-6) in treated models.
Comparison with BPC-157
| Feature | TB-500 | BPC-157 | |---------|--------|---------| | Origin | Thymus-derived | Gastric protein-derived | | Primary mechanism | Actin sequestration | NO pathway / VEGF | | Molecular weight | ~4963 Da | ~1419 Da | | Key research area | Cardiac, systemic repair | Tendon, GI, neurological | | Typical research dose (animal) | 2–5 mg/kg | 10–100 µg/kg |
Quality Standards for Research Procurement
When sourcing TB-500 for research, verify:
- HPLC purity certificate ≥98% (ideally ≥99%)
- Mass spectrometry confirmation of molecular weight
- Endotoxin (LAL) testing results
- Sterility testing where applicable
- Batch-specific COA with chromatogram
Pure Peptides supplies TB-500 at ≥99.6% HPLC purity with full batch COA documentation.
For research use only. Not intended for human administration.